02/26/2021 | Press release | Distributed by Public on 02/25/2021 23:45
Kuehne+Nagel successfully helped Sinovac Biotech Ltd., a leading biopharmaceutical company in China (Nasdaq: SVA) fulfill its first Covid-19 vaccine shipment from Beijing, China to the Dominican Republic.
Sinovac is one of the global players in Covid-19 vaccine research and development. To date, thevaccine has been approved for emergency use orconditional marketing authorisationin more than 20 countries, including China, Brazil, Indonesia, Turkey and Chile.
The pilot shipmentcontaining768,000 vialsof Covid-19 vaccine was stored in active temperature-controlled containers and arrived safely in Santo Domingo, the capital of theDominican Republic, on February 23, benefitting its citizens just before its Independence Day. The shipmentwas closely monitored and compliant with the most stringent standards toguarantee productintegrity.
Helen Yang, General Manager of Sinovac Biotech (Hong Kong) Limitedsaid: 'The Dominican Republic is 14,000 kilometers away from our factory in Beijing. During the ongoing pandemic, there are very few carriers connecting to this remote destination. However, Kuehne+Nagel responded to us with a feasible solution in just a short span of twelve hours. Even during the Chinese New Year holidays, the Kuehne+Nagel team was diligently preparing this shipment. We look forward to a collaborative partnership with Kuehne+Nagel.'
Siewloong Wong, President of Kuehne+Nagel Asia Pacific said: 'We couldn't be prouder to having started shipments of Sinovac Covid-19 vaccine. At Kuehne+Nagel, we leverage our global pharma & healthcare network and expertise to bring the Sinovac vaccine to the market. We truly appreciate the trust that Sinovac has bestowed upon us.'
Prior to this shipment, Kuehne+Nagel successfully fulfilled multiple crucial assignments for Sinovac, including an air charter from Beijing to Turkey for a door-to-door delivery of nearly a quarter-million flu vaccines. Kuehne+Nagel also helped with the shipment of Hepatitis A vaccine to Guatemala in South America as well as making nucleic acid detection kits available to people in Indonesia.
With offices all over the world, 240 GxP-certified operations and more than 3,000 dedicated pharma & healthcare specialists, Kuehne+Nagel has the capacity, the ability and the responsibility to play a vital role in the global distribution of COVID-19 vaccine.
With over 78,000 employees at 1,400 locations in over 100 countries, the Kuehne+Nagel Group is one of the world's leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions.